Sign Up Today and Learn More About Halda Therapeutics Stock
Invest in or calculate the value of your shares in Halda Therapeutics or other pre-IPO companies through EquityZen's platform.
Halda Therapeutics Stock (HADT)
Halda Therapeutics is a research-stage drug discovery company.
About Halda Therapeutics Stock
Founded
2018
Headquarters
New Haven, CT, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Halda Therapeutics Press Mentions
Stay in the know about the latest news on Halda Therapeutics
Halda Therapeutics Announces Appointment of Eyal Attar, MD, as Chief Medical Officer
biospace • Apr 22, 2025
First-ever RIPTAC enters clinic: all you need to know about this new cancer approach
labiotech • Mar 26, 2025
Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer
businesswire • Feb 24, 2025
Halda Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating HLD-0915 in Metastatic Castration-Resistant Prostate Cancer
biospace • Feb 24, 2025
Despite setbacks, investors remain bullish on CT’s bioscience sector, but changes in Washington raise uncertainty
hartfordbusiness • Feb 24, 2025
Halda Therapeutics Management
Leadership team at Halda Therapeutics
Founder
Craig M. Crews
President, Chief Executive Officer & Board Member
Timothy Shannon
Join now and verify your accreditation status to gain access to:
- Halda Therapeutics Current Valuation
- Halda Therapeutics Stock Price
- Halda Therapeutics Management
- Available deals in Halda Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Halda Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Halda Therapeutics Revenue and Financials
- Halda Therapeutics Highlights
- Halda Therapeutics Business Model
- Halda Therapeutics Risk Factors
- Halda Therapeutics Research Report from SACRA Research
Trading Halda Therapeutics Stock
How to invest in Halda Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Halda Therapeutics through EquityZen funds. These investments are made available by existing Halda Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Halda Therapeutics stock?
Shareholders can sell their Halda Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
